Antineoplastic agents. 600. from the south pacific ocean to the silstatins

George Pettit, Pablo M. Arce, Jean Chapuis, Christian B. Macdonald

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The recent advances in the development of antibody and other drug conjugates for targeted cancer treatment have further increased the need for powerful cancer cell growth inhibitors. Toward that objective we have extended our earlier discovery of the remarkable anticancer bacillistatins 1 and 2 from Bacillus silvestris to SAR and other structural modifications such as availability of a free hydroxy group for antibody-drug conjugate (ADC) and other prodrug linkage. That direction has resulted in seven structural modifications designated silstatins 1-8 (7a, 8a, 8b, 14a, 15a, 15b, 18a, and 18b), where the exceptional cancer cell growth inhibition of some of them are in the range GI50 10-3-10-4 μM/mL. Silstatin 7 (18a) was converted to a glucuronic conjugate (28) that displayed an impressive reduction in toxicity during transport.

Original languageEnglish (US)
Pages (from-to)510-523
Number of pages14
JournalJournal of Natural Products
Issue number3
StatePublished - Mar 27 2015

ASJC Scopus subject areas

  • Analytical Chemistry
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine
  • Organic Chemistry


Dive into the research topics of 'Antineoplastic agents. 600. from the south pacific ocean to the silstatins'. Together they form a unique fingerprint.

Cite this